Fundraising Fox
EnClear Therapies
Cambridge, US · Founded 2018 · Delaware corporation · 7 employees on LinkedIn · 7 known investors
Find your way into EnClear Therapies
475 people in our graph share verified history with the EnClear Therapies team — schools, employers, funds. One of them is your warm intro.
EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies. It is built by a multidisciplinary team with experience in platform and commercial market development.
Also known as EnClear Therapies
Founders & leadership
EnClear Therapies was founded in 2018 by Anthony DePasqua.
Board
Investors · 7
How we know: 20/20 HealthCare Partners LLC's portfolio page · funding news · Not right? Tell us
How we know: Dolby Family Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements$10.7M disclosed across 2 of 3 rounds · 2020–2024
▶$718.3KraisedMar 2024 · 8 investors · OtherRule 506(b)
- Jonathan FlemingDirector
- Jason CammDirector
- Kasper RoetDirector
- Anthony DePasquaExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $718.3K
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026EnClear Therapies is a neurotechnology company developing the EnTrega CSF Platform, a system for delivering precision dosing of therapeutics into the central nervous system via cerebrospinal fluid (CSF). The company's stated aim is to improve and extend the lives of patients with CNS disorders, including neurodegenerative diseases and CNS malignancies, by reaching areas of the CNS where drug exposure is most beneficial while limiting severe side effects and peripheral toxicity.
The company positions itself as an integrated neurotechnology business rather than a single-asset developer, using the EnTrega platform to build a pipeline of near-term programs. Its strategy has two components: an initial launch in neuro-oncology, which it describes as a $1.2 billion market need, and subsequent expansion through partnerships into neurodegenerative, lysosomal storage and autoimmune diseases with next-generation and personalized medicines. The company also references institutional partners alongside its program pipeline.
▸Full profile — market position, technology, go-to-market
Market position
EnClear Therapies positions itself as an integrated neurotechnology business built around a proprietary CSF delivery platform, with an initial neuro-oncology opportunity it sizes at $1.2 billion.
The company differentiates on closed-loop CSF control paired with integrated machine learning/AI to enable precision dosing, aiming for efficacious CNS drug levels with lower peripheral toxicity than conventional dosing approaches.
Technology
The EnTrega CSF Platform combines closed-loop control of cerebrospinal fluid with integrated machine learning and artificial intelligence to deliver precision dosing of CNS-directed therapeutics. The stated technical objective is to achieve efficacious drug levels in targeted regions of the central nervous system while reducing the risk of severe side effects and peripheral toxicity.
Go-to-market
The company plans to launch first in neuro-oncology and to expand its portfolio into additional CNS indications through partnerships, including with institutional partners, applying next-generation and personalized medicines on the EnTrega platform.
Patients with central nervous system disease, including CNS malignancies (neuro-oncology as the initial focus) and, subsequently, neurodegenerative, lysosomal storage and autoimmune diseases.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
3 people who came through EnClear Therapies went on to found or lead other companies.
Competitors · 2
by search overlap
Companies competing with EnClear Therapies for the same Google search keywords, organic and paid, via search-intersection analysis.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- EnClear Therapiesencleartherapies.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does EnClear Therapies do?
- EnClear Therapies develops the EnTrega CSF platform for precision dosing of CNS therapeutics.
- Who founded EnClear Therapies?
- EnClear Therapies was founded by Anthony DePasqua in 2018.
- Who are EnClear Therapies's investors?
- EnClear Therapies's investors include 20/20 HealthCare Partners LLC, Dolby Family Ventures, Flucas Ventures, Tachyon Ventures, VU Venture Partners, Amgen Ventures, Founders Fund.
- How much funding has EnClear Therapies raised?
- EnClear Therapies has disclosed $10.7M raised across 2 of its 3 known rounds.
- Where is EnClear Therapies headquartered?
- EnClear Therapies is headquartered in Cambridge, US.